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ManagementAbstract Objective: A 28-year-old male diagnosed with schizophrenia, maintaining well on
Olanzapine, developed akathisia soon after addition of Erythromycin for Pityriasis Rosea. This
prompted us to evaluate the relationship of Erythromycin and akathisia. Method: We report the
case and the literature focusing on akathisia as a possible adverse event of Erythromycin.
Results: Akathisia resolved after Erythromycin was stopped following 5 days of treatment.
Akathisia was possibly induced or precipitated with use of Erythromycin. Possible etiological rea-
sons of this clinically signiﬁcant association are discussed. Conclusion: Erythromycin, by itself, may
induce akathisia or precipitate akathisia in individuals by interfering with metabolism of other
culprit drugs.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Akathisia is an unpleasant sensation of ‘‘inner’’ subjective rest-
lessness that manifests objectively as inability to sit still, lifting
feet and constantly moving around (Brune, 2002). Akathisia is
a well known adverse effect of treatment with antipsychotic(both ﬁrst and second generation) drugs (Kumar and
Sachdev, 2009). However, the term was coined in 1901 by
Ladislav Haskovec, long before the introduction of antipsy-
chotics (Berrios, 1995; Haskovec, 1901). This may suggest
akathisia as an integral part of some disorders or as an adverse
effect of some drugs which have not yet been investigated.
Some other commonly implicated drugs are serotonin selective
reuptake inhibitors (SSRIs) (Walker, 2002) and anti-emetics
(metoclopramide, promethazine) (Tsuji et al., 2006).
Some other drugs such as Erythromycin, however, may
induce akathisia. According to FDA reports, akathisia has
been reported as a side effect of Erythromycin itself.
Erythromycin may also precipitate akathisia by either increas-
ing the blood concentration of the implicated drug or as an
additive effect with another implicated drug. It then becomes
difﬁcult to pinpoint the exact cause of akathisia, especially
when the drug in question is co-administered with a proven
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maintaining well on Olanzapine and developed akathisia soon
after addition of Erythromycin.2. Case report
A 28 year old unmarried Hindu Male, 12th Pass, resident of a
nuclear family of Delhi, was admitted in the Psychiatry
Department of a Tertiary Care General Hospital with history
of an insidious onset, continuous illness of 6 years duration
(since 2008), characterized by 2nd and 3rd person auditory hal-
lucinations, delusion of reference and persecution, disturbed
sleep, disorganized behavior (poor hygiene, collecting garbage,
not changing clothes, roaming in the streets and disrobing),
reduced self case and socio-occupational decline. The symptoms
worsened in the last 2 years. The patient presented to Hospital
in 2012 and was diagnosed with Schizophrenia. He was started
on Tab. Olanzapine 10 mg/per day (gradually increased to
20 mg/per day in next 2 months) and Tab. Trihexyphenidyl
2 mg/per day. The patient improved signiﬁcantly and main-
tained well on the same treatment for last 2 years. His Brief
Psychiatric Rating Scale (BPRS) score decreased to 12/126 from
48/126. During the course of treatment, the patient developed
rashes over his body and was referred to Dermatology depart-
ment for evaluation. The rashes were diagnosed as Pityriasis
Rosea and were treated with Tab. Erythromycin 250 mg (four
times/day) and T. Cetirizine 10 mg (once daily) for 5 days. On
4th day of starting Tab. Erythromycin, the patient developed
feeling of restlessness, anxiety, feeling to get up and move his
limbs. He would pace around constantly. He presented to
OPD again and the movements were diagnosed as Akathisia.
Tab. Propranolol 20 mg/per day was started for akathisia
but no improvement was reported. However, when Tab.
Erythromycin was stopped after scheduled 5 days, the patient
recovered spontaneously over next 3 days and the improvement
persisted even after immediately stopping T. Propranolol
(Barnes Akathisia Rating Scale; 4ﬁ 0). The patient continues
to be treated with Olanzapine (20 mg per day) and
Trihexyphenidyl (2 mg per day) without any further instances
of akathisia. The akathisia was supposed to be either directly
induced by Erythromycin or precipitated due to concomitant
use of Erythromycin with Olanzapine.3. Discussion
Akathisia is usually induced by drugs such as antipsychotics,
SSRIs and anti-emetics. Evidence from the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE)
and European First Episode Schizophrenia Trial suggests that
both First Generation Antipsychotic (FGA) and Second
Generation Antipsychotics (SGA) can equally cause akathisia
(Kahn et al., 2008; Lieberman et al., 2005). Akathisia can be
very debilitating for a person; hence it is important to properly
recognize and manage the cause immediately.
Akathisia due to Olanzapine use is well documented.
Olanzapine in the dose range of 5–20 mg induces akathisia in
approximately 10% of the patients (8), due to blockade of stri-
atal dopamine receptors. However, akathisia usually developswithin weeks after initiation or dose increase of a neuroleptic
drug. This was not the case here as patient was maintaining
well on same dose of Olanzapine for past 2 years before adding
Erythromycin and continues to maintain well after
Erythromycin was stopped.
Erythromycin is a bacteriostatic macrolide antibiotic useful
for the treatment of a number of bacterial infections.
Erythromycin is an inhibitor of the cytochrome P450 system
(Pai et al., 2000), which means that it can have a rapid effect
on levels of other drugs metabolized by this system, which
includes Olanzapine as well. Erythromycin is usually not
known to cause akathisia and no published reports are avail-
able implicating the role of Erythromycin in akathisia.
However, FDA reported akathisia in 34 patients taking
Erythromycin between January 2004 and October 2012 out
of a total of 4696 Erythromycin drug adverse event reaction
reports. Since FDA receives reports of the most severe cases
these numbers may therefore underrepresent the overall inci-
dence of all the adverse events.
In the index case, the temporal relationship suggests
Erythromycin as the causative molecule, but it is difﬁcult to
pinpoint the offending medication. Erythromycin may have
by itself induced akathisia; however it is unlikely as the onset
was within a few days of starting it. The other possibility is
that Erythromycin may have increased the blood concentra-
tion of Olanzapine leading to akathisia, due to inhibition of
cytochrome P450. However, Erythromycin predominantly
inhibits cytochrome CYP3A4 while Olanzapine is metabolized
primarily by CYP1A2 and to a lesser extent by CYP2D6 and
CYP3A4. The third possibility that seems more acceptable/
realistic is that Erythromycin might have precipitated akathisia
in a predisposed individual already on Olanzapine, probably
due to additive effect of both the compounds. Also,
Olanzapine in itself is an inhibitor of cytochrome P450
CYP3A complex involved in metabolism of Erythromycin,
which could have increased the serum concentration of
Erythromycin. Hence, the causality may be attributed to the
combined effect of both of these drugs.
It may be concluded that there are many drugs such as
Erythromycin, which may induce and precipitate akathisia.
Some of these drugs may be very commonly used in clinics.
Hence, it is important to put in more research regarding the
possibility of akathisia with these drugs and establish the
possibly implicated culprit molecules. This needs large scale
studies in future.References
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